Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia

Hee Won Chueh¹#, Sang Mee Hwang²#, Ye Jee Shim³, Jae Min Lee⁴, Hee Sue Park⁵, Joon Hee Lee², Youngwon Nam², Namhee Kim⁶, Hye Lim Jung⁷, Hyoung Soo Choi⁸, on behalf of Korean RBC Disorder Working Party

¹Department of Pediatrics, Dong-A University, College of Medicine, Busan, ²Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Department of Pediatrics, ³Keimyung University School of Medicine, Keimyung University Dongan Hospital, ⁴Yeungnam University Medical Center, Daegu, Department of Laboratory Medicine, ⁵Chungbuk National University Hospital, Cheongju, ⁶Dong-A University, College of Medicine, Busan, Department of Pediatrics, ⁷Sungkyunkwan University School of Medicine, Seoul, ⁸Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

Abstract

Although the prevalence of hereditary hemolytic anemia (HHA) is relatively low in Korea, it has been gradually increasing in recent decades due to increment in the proportions of hemoglobinopathies from immigrants of South East Asia, raising awareness of the disease among clinicians, and advances in diagnostic technology. As such, the red blood cell (RBC) Disorder Working Party (WP), previously called HHA WP of the Korean Society of Hematology (KSH) developed the Korean Standard Operating Procedures (SOPs) for the diagnosis of HHA in 2007. These SOPs have been continuously revised and updated following advances in diagnostic technology [e.g., flow cytometric osmotic fragility test (FOFT) and eosin-5-maleimide (EMA) binding test], current methods for membrane protein or enzyme analysis [e.g., liquid chromatography-tandem mass spectrometry (LC-MS/MS), ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), high-performance liquid chromatography (HPLC)], and molecular genetic tests using next-generation sequencing (NGS). However, the diagnosis and treatment of HHA remain challenging as they require considerable experience and understanding of the disease. Therefore, in this new Korean Clinical Practice Guidelines for the Diagnosis of HHA, on behalf of the RBC Disorder WP of KSH, updated guidelines to approach patients suspected of HHA are summarized. NGS is proposed to perform prior to membrane protein or enzyme analysis by LC-MS/MS, UPLC-MS/MS or HPLC techniques due to the availability of gene testing in more laboratories in Korea. We hope that this guideline will be helpful for clinicians in making diagnostic decisions for patients with HHA in Korea.

Key Words Hereditary hemolytic anemia, Diagnosis, Standard operating procedures

INTRODUCTION

Hereditary hemolytic anemia (HHA) is a rare but highly heterogeneous inherited genetic disease characterized by anemia due to premature red blood cell (RBC) destruction and intrinsic RBC defects [1]. The three main etiologies of HHA are disorders of the RBC membrane (membranopathy), disorders of the RBC enzyme (enzymopathy), and disorders of hemoglobin (hemoglobinopathy) [1]. The prevalence of HHA is very low in Korea because hereditary spherocytosis (HS) is less common in Asians than in Caucasians, occurring in 1 per 5,000 population, and Korea does not belong to the thalassemia belt [2]. However, the incidence of hemoglobinopathy in Korea has increased in recent years due to an increase in immigrants, especially women, from Southeast Asia through international marriages [3, 4]. The awareness of clinicians about the disease and advances in the diagnostic
technology also may have influenced the epidemiology of HHA in Korea [5, 6].

The RBC Disorder Working Party (WP), previously named HHA WP, of the Korean Society of Hematology (KSH), conducted a 10-year nationwide multicenter retrospective epidemiologic study of HHA in Korea from 2007 to 2016 [5]. Compared to the previous 10-year nationwide epidemiologic study of HHA in Korea from 1997 to 2006 [7], the proportions of hemoglobinopathies and enzymopathies have increased significantly in the last 10 years. Among the 369 newly diagnosed pediatric HHA patients in Korea, 71.3% had RBC membranopathies, 16.0% had hemoglobinopathies, 6.2% had RBC enzymopathies, and 6.5% had unknown etiologies. These data show the importance and necessity for the development and continuous improvement of the standardized diagnostic guidelines of HHA for clinical practitioners to suspect and diagnose HHA in Korean patients with anemia.

Patients with HHA may have similar clinical and laboratory findings. However, different therapeutic approaches may be required according to disease cause. Although splenectomy may be effective in the management of patients with HS, patients with hereditary stomatocytosis (HSt) do not benefit from splenectomy and are at increased risk of thromboembolic disorders after splenectomy [7, 8]. Thus, the RBC Disorder WP of the KSH had developed the Korean Standard Operating Procedures (SOPs) for the diagnosis of HHA in 2007 and had continuously updated the SOPs to ensure accurate and nationally standardized diagnostic methods and laboratory reports [9]. The initial Korean SOPs for the diagnosis of HHA were a step-by-step diagnostic process, including assessment of family history of anemia, gall stone or splenectomy, clinical examinations, and laboratory tests for anemia. These laboratory tests included complete blood count (CBC) with RBC index, peripheral blood morphology, iron study, bilirubin, lactate dehydrogenase (LDH), hapto globin, antiglobulin test, osmotic fragility test (OFT), hemoglobin electrophoresis, globin gene analysis, RBC membrane protein analysis, and RBC enzyme analysis [9].

Subsequently, SOPs were updated by introducing more sensitive screening methods for RBC membranopathies [e.g., flow cytometric OF test (FOFT) and eosin-5-maleimide (EMA) binding test] and current methods for membrane protein or enzyme analysis [e.g., liquid chromatography-tandem mass spectrometry (LC-MS/MS), ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), and high-performance liquid chromatography (HPLC)] [5, 9]. In addition, following recent advances in molecular diagnostic technologies, such as next-generation sequencing (NGS), the RBC Disorder WP of the KSH has developed an NGS gene panel for Korean HHA patients [10]. Considering the wider availability of gene testing in more laboratories in Korea, the panel included a proposal in the new Korean Clinical Practice Guidelines for the Diagnosis of HHA that NGS be performed prior to membrane protein or enzyme analysis by LC-MS/MS, UPLC-MS/MS, or HPLC techniques.

In this study, the authors attempted to update the SOP for HHA diagnosis on behalf of the RBC Disorder WP in KSH. Approaches for patients with anemia, suspected of HHA are described, including laboratory tests focused on HHA. We hope that this guideline may be helpful for clinicians in making diagnostic decisions for HHA patients in Korea.

GENERAL APPROACH TO THE PATIENT WITH HHA

History and clinical manifestations

The most common chief complaint of HHA is neonatal hyperbilirubinemia (within 48 hr of birth) requiring immediate medical intervention. With the exception of β-globin-associated HHA, most cases require more than just phototherapy, with some severe cases require exchange transfusion to avoid kernicterus [8]. The incidence of neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase (G-6PD) deficiency is higher in male patients due to X-chromosome-related inheritance, but G-6PD deficiency should also not be ruled out in females because they can also present with mild symptoms through X-chromosome lyonization [11]. Intrauterine symptoms in fetuses with HHA are common. Intrauterine anemia, hyperbilirubinemia, intrauterine growth retardation, hydrops fetalis, and preterm labor have been reported as complications of HHA, especially in HS and enzymopathies [8, 12].

β-globin-related HHAs such as β-thalassemia or sickle cell disease usually present with anemia at 4 to 6 months of age [13]. Patients typically present with chronic HA, ranging from asymptomatic to compensated hemolysis to severe anemia, some requiring chronic transfusion therapy. Although the disease severity differs, most HHA patients need cholecystectomy or splenectomy [8]. Rarely, some neonates with HA develop jaundice that resolve in the first few months of life. These patients might have unstable hemoglobinopathy due to mutations in the γ-globin chain that resolves as fetal hemoglobin is replaced by adults [12, 14].

Some patients also develop hemolytic events, such as aplastic crisis that is commonly caused by parvovirus B19 infection [15]. Membranopathies, sickle cell disease, and enzymopathies such as G-6PD deficiency may be diagnosed incidentally by presenting with aplastic crisis events. Hemoglobinopathies, such as sickle cell disease and thalassemia, usually present as extensive extravascular hemolysis with increased blood viscosity due to excessive globin chain [16]. This typically leads to deep vein thrombosis, edema, pain, peripheral ulcers, and circulatory problems. Depending on the severity of hemolysis, patients may also manifest typical bony abnormalities and severe hepatosplenomegaly, which occur relatively earlier than do other HHAs [17].

The peripartum period can also yield pertinent diagnostic information. Specifically, the method of delivery (with or without instrumentation), history of maternal hemorrhage (e.g., vaginal or placental), evidence of fetal distress, and the presence of multiple gestations may all be crucial evidence. Further information regarding the pathology of
the placenta and umbilical cord and its insertion may also
be useful. Family history should also be determined when
investigating causality of anemia in the newborn because
certain conditions of autosomal recessive (e.g., Fanconi’s ane-
mia), autosomal dominant or autosomal recessive [e.g., G-6PD deficiency] may be disease etiologies. Less spe-
cifically, a history of relatives with anemia, jaundice, or
splenectomy can also aid in directing further diagnostic evalua-
tions.

Finally, the patient’s history is essential for diagnosis. Particu-
larly, the gestational age and days of life at the time of
presentation, ethnicity/race, and sex of the infant are
all useful not only in determining a diagnosis of anemia,
but also in establishing etiology such as in G-6PD deficiency
and thalassemia. The diagnosis and etiology of neonatal and
infancy anemia can often be determined with a thorough
history taking; however, in certain situations, further diag-
nostic work-up may be required.

Physical examination
Intra- or extra-vascular premature destruction of RBCs
results in anemia and an increase in production of uncon-
jugated bilirubin, which leads to jaundice [18]. In the case
of intravascular hemolysis, hemoglobin may be excreted into
the urine (hemoglobinuria), leading to dark red-brown col-
ored urine and therefore, HHA is suspected when the patient
shows clinical findings of anemia, jaundice, and splenome-
galy (Fig. 1). HHA should also be considered when neonates
have jaundice requiring phototherapy or exchange transfusion.
However, the severity of jaundice or hyperbilirubinemia
does not predict the severity of the disease in the future
[19].

Among HHA patients, those with membranopathies (HS
or HE) generally show extravascular hemolysis. Although
most patients with HS have mild HA, patients with autosomal
recessive HS have severe anemia, which is transfusion de-
pendent [19]. Further, although majority of patients with
HS have mild to moderate splenomegaly [20, 21] and spleno-
mealy itself assists in the diagnosis of HS, it has little clinical
significance [20, 21]. HS patients with well-compensated
anemia are diagnosed later in life from the related chol-
elithiasis [14]. Hemoglobinopathies (thalassemia or sickle
cell disease) generally show extravascular hemolysis. Patients
with thalassemia major show typical clinical features of facial
changes (enlarged maxillary sinuses) from hematopoiesis or
blood cell production and such changes in the face promote
infections of the ears, nose, and throat in patients with tha-
lassemia major. Chronic transfusion-dependent anemia and
iron overload, cardiomyopathy, diabetes mellitus, hypo-
pituitarism, hypoparathyroidism, hypothyroidism, or test-
ticular/ovarian failure are frequent in adults with thalassemia
major [13].

Enzymopathies (G-6PD deficiency or pyruvate kinase (PK)
deficiency) generally present with intravascular hemolysis
[22]. In the case of G-6PD deficiency, intra- and extravascular
hemolysis can occur. In patients with G-6PD deficiency,
jaundice usually develops during the first postnatal day [19].
After infancy, most patients with G-6PD deficiency do not
have anemia or jaundice at baseline, but hemolysis is trig-
gered by oxidative stressors including medication, infections
or fava beans. After exposure to oxidative stressors, acute
HA develops with pallor, jaundice, fatigue, back pain, and
red-brown urine in patients with G-6PD deficiency [19].

![Fig. 1. Updated standard operating procedure for the diagnosis of hereditary hemolytic anemia by the RBC Disorder Working Party of the Korean Society of Hematology.](image_url)
Meanwhile, patients with PK deficiency have differing clinical course. Some patients with PK deficiency have lifelong fully compensated or mild anemia, while others have transfusion-dependent anemia [1]. Hyperbilirubinemia in neonates with PK deficiency can be severe and require an exchange transfusion. Cholelithiasis or transfusion-dependent iron overload are common in cases of severe phenotypes of PK deficiency and the degree of hemolysis can be exacerbated during infections or pregnancy [23]. Splenomegaly is not prominent, and the benefits of splenectomy vary by case [12]. Further specific findings of physical examination of patients with HHA are shown in Table 1 [18, 24].

### Laboratory tests for screening

Laboratory tests to be performed in patients suspected of HHA are shown in Fig. 1. Testing commonly starts from complete blood count (CBC) and reticulocyte count. The WHO criteria for anemia vary with age and sex, as shown in Table 2 [25]. The corrected reticulocyte count (CRC, %) and reticulocyte production index (RPI) are calculated as follows:

\[
\text{CRC} = \frac{\text{reticulocyte} \times \text{patient hematocrit}}{90} \\
RPI = \frac{\text{CRC}}{\text{maturation time}} \quad \text{(maturation time depends on hematocrit)}
\]

In general, RPI reflects the erythropoietic activity of bone marrow, with RPI > 3 indicating an appropriate bone marrow response and RPI < 2 indicating an inadequate response to correct anemia [27]. The severity of anemia reflects the clinical severity of hemolytic diseases [28], and individuals may show normal hemoglobin levels with reticulocytosis, suggesting compensated hemolysis or reticulocytopenia despite hemolysis in other cases [28]. Red cell indices can be used for differential diagnosis. HS patients have elevated mean corpuscular hemoglobin concentration (MCHC) from relative dehydration, suggesting the presence of spherocytes with the loss of membrane surface area relative to intracellular volume. In HA patients with low mean corpuscular volume (MCV) and mean corpuscular hemoglobin, the work-up of thalassemia should follow once iron deficiency is ruled out. Markers of hemolysis, including elevated lactate dehydrogenase (LDH), urinary and fecal urobilinogen, unconjugated hyperbilirubinemia, and decreased serum haptoglobin are present in varying degrees in HA [29]. Direct antiglobulin testing (direct Coombs’ test) is performed to detect antibodies or complement system factors that are bound to RBC surface antigens. Patients who test positive are suspected for HA caused by immune-mediated causes rather than intrinsic defects of RBC membranes or enzymes [22].

### Peripheral blood smear

A peripheral blood smear (PBS) can be used for the differential diagnosis of nonimmune HA. Spherocytic red cells are predominant red cell-shaped abnormalities in HS [30]. Defects in the RBC membrane due to various genetic alterations lead to spherocyte formation [30]. Although spherocytes are predominant, additional red cell morphologies can also be observed [14]. Anisocytosis is noted in patients with ANK1-associated HS, mushroom-shaped red cells are characteristic of band 3 (SLC4A1) deficiency, and acanthocytes/echinocytes are associated with SPTA1-associated HS [30]. Ovalocytes and ovalostomatocytes have been observed in EPB42-associated HS [30]. Other inherited red cell membrane disorders include HbE and HbS. Mild HE is characterized by remarkable elliptocytosis without HA, whereas moderate to severe HE commonly presents with fragmented red cells associated with HA [14]. Meanwhile, HSt presents with a high number of stomatocytes, but the red cell morphology is relatively normal [14]. In addition, red cell inclusions can aid in the diagnosis of non-immune HA. Heinz bodies are commonly observed in abnormalities of alpha and beta hemoglobinopathies [31]. Hypochromic anemia is also a typical finding of unstable hemoglobin in PBS. Meanwhile, although PBS findings are not critical for diagnosis, they may be helpful in disorders of erythrocyte metabolism. For example, basophilic stippling is characteristic of pyrimidine 5’ nucleotidase (P5N) deficiency [31]. Occasionally, neonatal HA causes G-6PD deficiency or PK deficiency to overlap with infantile pyknocytosis, which can confuse the differential diagnosis [21, 32]. Postponing morphology tests can sometimes be considered

### Table 1. Specific findings of physical examination of patients with hereditary hemolytic anemia.

| Physical examination                  | Hereditary hemolytic anemia            |
|-------------------------------------|---------------------------------------|
| Ulcers on lower extremities         | Sickle cell disease, thalassemia       |
| Frontal bossing, prominence of the malar and maxillary bones | Chronic hemolysis including thalassemia major |
| Tortuosity of the conjunctival and retinal vessels | Sickle cell disease |
| Microaneurysms of retinal vessels | Sickle cell disease                    |
| Cataracts                           | G-6PD deficiency                      |
| Vitreous hemorrhages                | S hemoglobinopathy                    |

**Table 2.** WHO reference range for hemoglobin levels diagnostic of anemia.

| Population                                      | Hemoglobin (g/dL) |
|-------------------------------------------------|-------------------|
| Children 6–59 month                             | < 11.0            |
| Children 5–11 years                             | < 11.5            |
| Children 12–14 years                            | < 12.0            |
| Non-pregnant women (15 yr of age and above)     | < 12.0            |
| Pregnant women                                  | < 11.0            |
| Men (15 yr of age and above)                    | < 13.0            |

Abbreviation: G-6PD, glucose-6-phosphate dehydrogenase.
until at least 6 months of age [21].

**Osmotic fragility test and eosin-5-maleimide binding test by flow cytometry**

OFT has been performed for HS screening to testing the capability of RBCs to incorporate hypotonic solutions. However, because of its low sensitivity, specificity, and lack of standardization, OFT is not recommended, and FOFT has been introduced [33-35]. FOFT measures the difference in RBC at baseline with normal saline and after incubation with hypotonic saline. Although protocols vary among laboratories, FOFT have been shown to have higher sensitivity and specificity than OFT [34, 36]. Eosin-5-maleimide (EMA) is thought to bind to membrane proteins (band 3, CD47, Rh protein, and Rh glycoprotein) on RBCs, which are indirectly associated with the spectrin-based RBC cytoskeleton [35, 37]. A reduction in fluorescence intensity of EMA-labeled RBCs on flow cytometry indicates a membrane protein-associated RBC disorder. Patients with a family history of HS, typical clinical features (splenomegaly), and laboratory features (spherocytes, increased MCHC, increase in reticulocytes) do not require additional tests according to the guidelines for the diagnosis of HS [21].

However, when the diagnosis is equivocal, cryohemolysis and EMA binding tests are recommended for screening. Although the EMA binding test is highly sensitive for HS, Southeast Asian ovalocytosis (SAO), cyrohydrocytosis, congenital dyserythropoietic anemia (CDA) type II, and hereditary pyropoikilocytosis can also present with fluorescence intensity in the same range as HS [35, 38]. Thus, the clinical presentation and PBS results should be reviewed in conjunction. Some HS patients with isolated ankyrin deficiency exhibit normal fluorescence. The cutoff value for HS varies by laboratory because of the differing EMA preparations, and thus, it should be established according to the testing site [39]. Further, there exists a gray zone between normal controls and HS [40], and family studies and other tests may be required. Both FOFT and EMA testing are available in several laboratories in Korea [33, 39], and they can be ordered for patients suspected of HS.

**High-performance liquid chromatography and hemoglobin electrophoresis**

Hemoglobinopathies are screened by either HPLC or isoelectric focusing in the United States [41]. In Korea, hemoglobinopathies are evaluated using HPLC or hemoglobin electrophoresis, which is available in many laboratories [42]. Hemoglobin fractions are separated based on their ionic interaction, and each hemoglobin has its own retention time, which is measured from the time of sample injection into the HPLC to the maximum point of each peak. Unknown hemoglobin fractions are identified by comparison with known hemoglobin retention times [43]. With electrophoresis, charged molecules are separated by their electrophoretic mobility, either in alkaline or acidic pH conditions. In alkaline electrophoresis (pH 8.6-9.2) with cellulose acetate, more negatively charged hemoglobins move to the anode faster, and the separation of HbA, HbA<sub>2</sub>, HbF, HbS, and HbC is reliable. In acid electrophoresis with citrate agar, HbS can be separated from HbD and HbG, and HbC from HbE and HbO [44, 45]. Capillary zone electrophoresis (CZE) is performed in an alkaline buffer (pH 9.4) where hemoglobin fractions migrating from the anodic end of the capillary appear in specific zones to the cathodic end, and detection occurs at 415 nm [46]. Although the reference range may vary by method, it is usually 96% for HbA, <1% for HbF, and 2.5-3.5% for HbA<sub>2</sub>. In β-thalassemia, HbA is decreased and HbA<sub>2</sub> is slightly increased (<10%), with variably increased HbF. An HbA<sub>2</sub> level above 10% suggests variant hemoglobin rather than β-thalassemia. The decrease in HbA levels depends on the genetic variations in β-thalassemia. Meanwhile, in α-thalassemia, HbA<sub>2</sub> is normal or slightly decreased, and HbH or HbBart can be present in newborns. In Korea, abnormal CZE or HPLC results are confirmed by genetic testing, usually with Sanger sequencing and/or multiplex ligation probe amplification (MLPA) [42].

**RBC membranopathies**

RBC membrane disorders can be categorized into two groups: 1) RBC disorders caused by membrane structural defects (e.g., HS, HE, hereditary pyropoikilocytosis, and SAO) and 2) RBC disorders caused by altered membrane transport function (e.g., HSt, familial pseudohyperkalemia, and cryohydrocytosis) [47, 48]. Although genetic testing is an important tool for differential diagnosis [49, 50], approximately 50% of cases are undiagnosed despite NGS testing [47]. Further, several atypical cases of RBC membrane structure defects may need quantification of the membrane proteins for mutations not consistent with the phenotype [51] and for diagnostic confirmation according to the ICSH guidelines [52]. Quantification of RBC membrane proteins has been traditionally performed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [47, 52, 53]. However, more advanced mass-spectrometry-based techniques with matrix-assisted laser desorption/ionization-time of flight mass spectrometry [54] or LC-MS/MS [54, 55] have been used recently, but these are currently unavailable in Korea. Genetic testing can be considered in cases of suspected RBC membranopathy.

HS not only has highly variable phenotypes, but is also associated with genetic variants of cytoskeleton and transmembrane protein quantitative deficiencies, including ankyrin, erythrocytic α- and β-spectrin chains, band 3 protein, and protein 4.2 [29, 47]. The most frequently reported variants in HS are deficiency of ankyrin and band 3 proteins [52, 56]. Approximately 8-11% of patients have no detectable reductions in membrane proteins [52]. Membrane protein quantification by SDS-PAGE can be helpful in differentiating CDA type II from HS [47].

HE has defects in the proteins of the junctional complex (protein 4.1) and spectrin chains, which are caused by autoso-
RBC enzymopathies

Classical spectrophotometric methods to measure RBC enzyme activity involve specific reactions set up for each RBC enzyme, and changes in cofactor substrates (NAD+, NADP+, NADH, or NADPH) are measured at 340 nm [57]. These classical methods are generally labor intensive and time consuming because they require multiple reactions for each specific enzyme, and each enzyme must be measured separately. To overcome these disadvantages, LC-MS/MS-based multiplex RBC enzyme assays have been developed to measure the activities of enzymes implicated in RBC enzymopathies.

The current mainstream method for measuring RBC enzyme activities in Korea is an ion-pairing, UPLC-MS/MS method [58], which measures the activities of six major RBC enzymes, namely, G-6PD, PK, P5N, hexokinase (HK), triosephosphate isomerase (TPI), and adenosine deaminase (AD). The enzyme activities of five of these six enzymes (G-6PD, PK, P5N, HK, and AD) are measured in a one-step process. The respective enzyme reaction products, namely, 6-phosphogluconate, pyruvate, cytidine, C5-glucose-6-phosphate, and inosine, are directly measured by LC-MS/MS. For TPI, the primary reaction product (dihydroxyacetone phosphate) is indistinguishable from the substrate (glyceraldehyde-3-phosphate) on mass spectrometry. Therefore, a secondary reaction with α-glycerophosphate dehydrogenase is performed, which allows the measurement of the secondary reaction product (i.e., glyceraldehyde-3-phosphate) via LC-MS/MS. RBC enzyme activity results are reported in mg/min/gHb for G-6PD and PK and in μg/min/gHb for P5N, HK, TPI, and AD. Current reference levels, evaluated from 83 normal controls, are 0.96–3.14 mg/min/gHb for G-6PD; 1.01–3.01 mg/min/gHb, PK; 9.5–35.7 μg/min/gHb, P5N; 132–532 μg/min/gHb, HK; 423–961 μg/min/gHb, TPI; and 86.5–660.9 μg/min/gHb, AD, respectively.

The limitation of the current UPLC-MS/MS RBC enzyme activity assay is that it covers only six enzymes. Although deficiencies in the aforementioned six enzymes contribute to the majority of RBC enzymopathy cases, other enzymes including adenylate kinase, aldolase, phosphofructokinase, phosphoglycerate kinase, glucose-6-phosphate isomerase, glutathione reductase, and glutathione synthetase are also known to be associated with RBC enzymopathies [59]. Thus, clinicians should be clinically aware of which RBC enzymes are being tested and should not completely rule out any untested diagnoses. Furthermore, there are some notes of caution when interpreting enzyme assay results [31]. The in vivo environment may differ to laboratory-prepared, in vitro enzyme reactions. False masking of enzyme activity deficiency can occur under contamination by transfused normal RBCs or by glycolytic enzymes in leukocytes, highlighting the importance of leukocyte depletion in the sample preparation step. Moreover, the reported results are the averages of RBC enzyme activities, which may not accurately demonstrate activities in RBC subpopulations. Thus, possible variables such as reticulocytosis should be identified and considered before interpretation of RBC enzyme activity results.

Hemoglobinopathies

A retrospective epidemiologic study of HHA in Korea showed that majority of hemoglobinopathies were β-thalassemia (83.1%) and α-thalassemia minor (15.3%) [5]. In the case of β-thalassemia, mutation is mainly a single nucleotide variation in the HBB gene, and is detectable by the sequence analysis. However, it can also include variants in noncoding regions and, rarely, large deletions. If only one or no pathogenic variant is identified through HBB sequencing, deletion/duplication analysis is performed. In contrast, in the case of α-thalassemia, approximately 85% of all causative mutations are deletions in the HBA1 or HBA2 gene. Therefore, MLPA should be performed first, and sequence analysis of HBA1 and HBA2 can be performed if a common deletion is not identified. However, because MLPA is not covered by health insurance, MLPA is not routinely performed, and thus, the incidence rate of HHA may be underestimated in Korea [5].

Genetic testing for HHA

Accurate diagnosis of HHA is challenging because the clinical features may overlap even when the etiology is completely different. Thus, genetic testing is recommended if (i) routine studies have failed or achieved inconclusive to identify the causative mechanism; (ii) transfusions have recently been administered, leading to confounding biochemical and other testing due to mixed RBC populations; and (iii) the patient is a newborn [48]. As various genetic mechanisms regulating the function of RBCs have been elucidated [48, 60], genetic testing is increasingly being used for the confirmatory diagnosis of HHA in Korea. Until recently, molecular diagnosis has primarily been performed using Sanger sequencing techniques, typically by sequencing single genes [61]. Targeted gene panels have been developed and applied to routine molecular diagnosis for undiagnosed patients and family members of HHA [61, 62]. In addition, they are preferred over whole exome or whole genome sequencing due to lower cost and turn-around time, decreased complexity of data analysis, better coverage over the regions of interest, and reduced incidental findings [63].

The RBC Disorder WP of the KSH has developed a targeted gene panel that covers genes associated with RBC membraneopathy, enzymopathy, and other diseases that have overlapping features with HHA (Table 3). NGS testing can be considered prior to RBC enzyme or membrane protein analysis because of the wider availability of genetic testing in Korea. Phenotypic analysis can then be used to support the
Table 3. Hereditary hemolytic anemia-related genes recommended for gene panel test.a)

| Gene symbol | Gene name                                      | OMIM     | Phenotype                                           | Inheritance |
|-------------|-----------------------------------------------|----------|-----------------------------------------------------|-------------|
| AK1         | Adenylate kinase 1                            | 103000   | Hemolytic anemia due to adenylate kinase deficiency  | AR          |
| ANK1        | Ankyrin 1                                      | 612641   | Spherocytosis, type 1                               | AD, AR      |
| EPB41       | Erythrocyte membrane protein band 4.1         | 130500   | Elliptocytosis-1                                   | AR          |
| EPB42       | Erythrocyte membrane protein band 4.2         | 177707   | Spherocytosis, type 5                              | AR          |
| G6PD        | Glucose-6-phosphate dehydrogenase             | 305900   | Hemolytic anemia, G6PD deficient                    | XLD         |
| GCLC        | Glutamate-cysteine ligase catalytic subunit    | 606857   | Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency | AR          |
| GPI         | Glucose-6-phosphate isomerase                 | 172400   | Hemolytic anemia, nonspherocytic, glucose phosphate isomerase deficiency | AR          |
| GPX1        | Glutathione peroxidase 1                      | 138320   | Hemolytic anemia due to glutathione peroxidase deficiency | AR          |
| GSR         | Glutathione-disulfide reductase               | 138300   | Hemolytic anemia due to glutathione synthetase deficiency | AR          |
| GSS         | Glutathione synthetase                        | 601002   | Hemolytic anemia due to glutathione synthetase deficiency | AR          |
| HK1         | Hexokinase 1                                  | 142600   | Hemolytic anemia due to hexokinase deficiency       | AR          |
| KCNN4       | Potassium calcium-activated channel subfamily N member 4 | 602754   | Dehydrated hereditary stomatocytosis 2             | AD          |
| NT5C3A      | 5'-nucleotidase, cytosolic IIIA               | 6062240  | Anemia, hemolytic, due to UMPH1 deficiency          | AR          |
| PGK1        | Phosphoglycerate kinase 1                     | 311800   | Phosphoglycerate kinase 1 deficiency               | XLR         |
| PIEZO1      | Piezo type mechanosensitive ion channel component 1 | 611184   | Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema | AD          |
| PKLR        | Pyruvate kinase L/R                           | 609712   | Pyruvate kinase deficiency                         | AR          |
| RHAG        | Rh associated glycoprotein                    | 180297   | Overhydrated hereditary stomatocytosis             | AD          |
| SLC4A1      | Solute carrier family 4 member 1              | 109270   | Spherocytosis, type 4, Ovalocytosis, SA type, distal renal tubular acidosis 4 with hemolytic anemia | AD/AR       |
| SPTA1       | Spectrin alpha, erythrocytic 1                | 182860   | Elliptocytosis-2, pyropoikilocytosis, spherocytosis, type 3 | AD/AR       |
| SPTB        | Spectrin beta, erythrocytic                   | 182870   | Elliptocytosis-3, spherocytosis, type 2             | AD/AR       |
| TPI1        | Triosephosphate isomerase                     | 190450   | Hemolytic anemia due to triosephosphate isomerase deficiency | AR          |
| UGT1A1      | UDP glucuronosyltransferase family1 membrane A1| 191740   | Crigler-Najjar syndrome, Gilbert syndrome           | AR          |

a)Other genes such as HBA1, HBA2, HBB may be included for differential diagnosis of hemoglobinopathies. Abbreviations: AD, autosomal dominant; AR, autosomal recessive; OMIM, Online Mendelian inheritance in Man; XLD, X-linked disease; XLR, X-linked recessive.

molecular findings. However, the NGS panel of RBC Disorder WP or many other laboratories do not include testing for hemoglobinopathies because specific considerations are necessary regarding detection of large deletion/duplication, variants in introns, and copy number variations. All genetic tests should be designed to cover the major coding regions and intronic flanking regions of the gene. Each laboratory should validate its performance before clinical application [64]. Given that genetic tests have limited capability to identify variants of uncertain significance or to detect variants that do not explain the underlying phenotype, the results should be reviewed by professional geneticists.

CONCLUSION

HHAs are challenging to diagnose because of the many confounding factors in the clinical setting, thus confusing clinicians. However, technological advances have enabled the elucidation of the pathophysiology of many HHAs, and diagnostic tests are being updated. In addition, new technologies such as LC-MS/MS or NGS cover many diseases through a single test, enabling clinicians to gather more information simultaneously. However, accurate history taking and physical examination remain the most important diagnostic strategy for HHA. For patients suspected of having HHA, family history, past medical history, clinical pre-
sentation, and physical examination should be considered in the assessment in addition to sex and race, and the next step can be decided according to the PBS results. If spherocytes or other features of membranopathy are present, the EMA-binding test should be performed first. If PBS shows features suspected of thalassemia, MLPA or genetic testing should be selected for hemoglobin genes. If PBS findings are inconclusive, an enzyme test or NGS should be considered. However, there are limitations in current SOPs, and many HHAs cannot be diagnosed through the methods mentioned earlier. The recommended tests are now commercially available in Korea, and the RBC Disorder WP and the KSH will make any effort to update and improve the diagnostic SOPs of HHA. We hope that this report will be helpful in the diagnostic workup for patients with HHA in Korea.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Haley K. Congenital hemolytic anemia. Med Clin North Am 2017;101:361-74.
2. Ahn DH, Sohn KC, Kang IJ, et al. Statistical analysis of hemolytic anemia in Korea. Korean J Hematol 1991;26:445-61.
3. Kim YP, Joh JY, Shin IS. Family function of the families consisting of Asian immigrant women living in South Korea: a 3-year longitudinal study. Asia Pac J Public Health 2015;27:NP2702-11.
4. Lee YK, Kim HJ, Lee K, et al. Recent progress in laboratory diagnosis of thalassemia and hemoglobinopathy: a study by the Korean Red Cell Disorder Working Party of the Korean Society of Hematology. Blood Res 2019;54:17-22.
5. Shim YJ, Jung HL, Shin HY, et al. Epidemiological study of hereditary hemolytic anemia in the Korean pediatric population during 1997-2016: a nationwide retrospective cohort study. J Korean Med Sci 2020;35:e279.
6. Risinger M, Embereb M, Kalfa TA. Rare hereditary hemolytic anemias: diagnostic approach and considerations in management. Hematol Oncol Clin North Am 2019;33:373-92.
7. Park ES, Jung HL, Kim HJ, et al. Hereditary hemolytic anemia in Korea from 2007 to 2011: a study by the Korean Hereditary Hemolytic Anemia Working Party of the Korean Society of Hematology. Blood Res 2013;48:211-6.
8. Chueh HW. Treatment and management of late complications in hereditary hemolytic anemia. Clin Pediatr Hematol Oncol 2016;23:1-7.
9. Jung HL. A new paradigm in the diagnosis of hereditary hemolytic anemia. Blood Res 2013;48:237-9.
10. Choi HS, Choi Q, Kim JA, et al. Molecular diagnosis of hereditary spherocytosis by multi-gene target sequencing in Korea: matching with osmotic fragility test and presence of spherocyte. Orphanet J Rare Dis 2019;14:114.
11. Cortesi V, Manzoni F, Raffaelli G, et al. Severe presentation of congenital hemolytic anemias in the neonatal age: diagnostic and therapeutic issues. Diagnostics (Basel) 2021;11:1549.
12. Grace RF, Bianchi P, van Beers EJ, et al. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood 2018;131:2183-92.
13. Marengo-Rowe AJ. The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 2007;20:27-31.
14. Mohandas N. Inherited hemolytic anemia: a possessive beginner’s guide. Hematology Am Soc Hematol Educ Program 2018;2018:377-81.
15. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
16. Ghosh K, Ghosh K, Agrawal R, Nadkarni AH. Recent advances in screening and diagnosis of hemoglobinopathy. Expert Rev Hematol 2020;13:13-21.
17. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int 2011;108:532-40.
18. Dhaliwal G, Corneit PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician 2004;69:2599-606.
19. Noronha SA. Acquired and congenital hemolytic anemia. Pediatr Rev 2016;37:235-46.
20. Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004;126:455-74.
21. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ, General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis—2011 update. Br J Haematol 2012;156:37-49.
22. Phillips J, Henderson AC. Hemolytic anemia: evaluation and differential diagnosis. Am Fam Physician 2018;98:354-61.
23. Zanella A, Bianchi P. Red cell pyruvate kinase deficiency: from genetics to clinical manifestations. Baillieres Best Pract Res Clin Haematol 2000;13:57-81.
24. Lux SE. Disorders of the red cell membrane. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux IV S, eds. Nathan and Oski’s hematology of infancy and childhood. 8th ed. Philadelphia, PA: Elsevier Saunders, 2015:515-79.
25. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland: World Health Organization, 2011.
26. Hillman RS. Characteristics of narrow production and reticulocyte maturation in normal man in response to anemia. J Clin Invest 1969;48:443-53.
27. Bracho FJ, Osorio IA. Evaluation of the reticulocyte production index in the pediatric population. Am J Clin Pathol 2020;154:70-7.
28. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hereditary anemia. Dis Markers 2015;2015:635670.
29. Sadrzadeh SM, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004;121(Suppl):S97-104.
30. Risinger M, Kalfa TA. Red cell membrane disorders: structure meets function. Blood 2020;136:1250-61.
31. Gallagher PG. Diagnosis and management of rare congenital nonimmune hemolytic disease. Hematology Am Soc Hematol Educ Program 2015;2015:392-9.
32. Yaish HM, Christensen RD, Lemons RS. Neonatal nonimmune hemolytic anemia. Curr Opin Pediatr 2017;29:12-9.
33. Won DI, Sub JS. Flow cytometric detection of erythrocyte osmotic fragility. Cytometry B Clin Cytom 2009;76:135-41.
34. Arora RD, Dass J, Maydeo S, et al. Flow cytometric osmotic fragility test and eosin-5'-maleimide dye-binding tests are better than conventional osmotic fragility tests for the diagnosis of hereditary spherocytosis. Int J Lab Hematol 2018;40:335-42.
35. King MJ, Behrens J, Rogers C, Flynn C, Greenwood D, Chambers K. Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000;111:924-33.
36. Ciepiela O, Adamowicz-Salach A, Łazowska M, Kotula I. Flow cytometric osmotic fragility test: increased assay sensitivity for clinical application in pediatric hematology. Cytometry B Clin Cytom 2018;94:189-95.
37. King MJ, Smythe JS, Mushens R. Eosin-5'-maleimide binding to band 3 and Rh-related proteins forms the basis of a screening test for hereditary spherocytosis. Br J Haematol 2004;124:106-13.
38. Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012;97:516-23.
39. Park SH, Park CJ, Lee BR, et al. Comparison study of the eosin-5'-maleimide binding test, flow cytometric osmotic fragility test, and cryohemolysis test in the diagnosis of hereditary spherocytosis. Am J Clin Pathol 2014;142:474-84.
40. Hunt L, Greenwood D, Heimpel H, Noel N, Whiteway A, King MJ. Toward the harmonization of result presentation for the eosin-5'-maleimide binding test in the diagnosis of hereditary spherocytosis. Cytometry B Clin Cytom 2015;88:50-7.
41. Bender MA, Yusuf C, Davis T, et al. Newborn screening practices and alpha-thalassemia detection - United States, 2016. MMWR Morb Mortal Wkly Rep 2020;69:1269-72.
42. Lee HJ, Shin KH, Kim HH, et al. Increased prevalence of thalassemia in young people in Korea: impact of increasing immigration. Ann Lab Med 2019;39:133-40.
43. Joutovsky A, Hadzi-Nesic J, Narayanan H. HPLC retention time as a diagnostic tool for hemoglobin variants and hemoglobinopathies: a study of 60000 samples in a clinical diagnostic laboratory. Clin Chem 2004;50:1736-47.
44. Kim JE, Kim BR, Woo KS, Kim JM, Park JJ, Han JY. Comparison of capillary electrophoresis with cellulose acetate electrophoresis for the screening of hemoglobinopathies. Korean J Lab Med 2011;31:238-43.
45. McPherson RA, Pincus MR. Henry's clinical diagnosis and management by laboratory methods e-book. 24th ed. Philadelphia, PA: Elsevier Health Sciences, 2021.
46. Borbely N, Phelan L, Szidlo R, Bain B. Capillary zone electrophoresis for haemoglobinopathy diagnosis. J Clin Pathol 2013;66:29-39.
47. Iolascon A, Andolfi I, Russo R. Advances in understanding the pathogenesis of red cell membrane disorders. Br J Haematol 2019;187:13-24.
48. King MJ, Zanella A. Hereditary red cell membrane disorders and laboratory diagnostic testing. Int J Lab Hematol 2013;35:237-43.
49. Gambale A, Iolascon A, Andolfi I, Russo R. Diagnosis and management of congenital dyserythropoietic anemias. Expert Rev Hematol 2016;9:283-96.
50. Russo R, Gambale A, Langella C, Andolfi I, Unal S, Iolascon A. Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: definition of clinical and molecular spectrum and identification of new diagnostic scores. Am J Hematol 2014;89:E169-75.
51. Russo R, Andolfi I, Manna F, et al. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol 2018;93:672-82.
52. King MJ, Garçon L, Hoyer JD, et al. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015;37:304-25.
53. Lee YK, Cho HI, Park SS, et al. SDS-PAGE analysis of red cell membrane proteins in hereditary hemolytic anemia. Korean J Hematol 1999;34:559-67.
54. Şener LT, Aktan M, Albeniz G, Şener A, Üstek D, Albeniz I. Identification of red blood cell membrane defects in a patient with hereditary spherocytosis using next-generation sequencing technology and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Mol Med Rep 2019;19:3912-22.
55. Bryk AH, Wiśniewski JR. Quantitative analysis of human red blood cell proteome. J Proteome Res 2017;16:2752-61.
56. Delaunay J. The molecular basis of hereditary red cell membrane disorders. Blood Rev 2007;21:1-20.
57. Peters AL, Veldhuis M, van Leeuwen K, et al. Comparison of spectrophotometry, chromate inhibition, and cytofluorometry versus gene sequencing for detection of heterozygously glucose-6-phosphate dehydrogenase-deficient females. J Histochem Cytochem 2017;65:627-36.
58. Park CM, Lee K, Jun SH, Song SH, Song J. Ultra-performance liquid chromatography-tandem mass spectrometry-based multiplex enzyme assay for six enzymes associated with hereditary hemolytic anemia. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1060:76-83.
59. Glader B. Hereditary hemolytic anemias due to red blood cell enzyme disorders. In: Greer JP, Arber DA, Glader B, et al, eds. Wintrobe’s clinical hematology. 13th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:728-45.
60. van der Harst P, Zhang W, Mateo Leach I, et al. Seventy-five genetic loci influencing the human red blood cell. Nature 2012;492:369-75.
61. Agarwal AM, Nussenzweig RH, Reading NS, et al. Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anemias. Br J Haematol 2016;174:806-14.
62. Roy NB, Wilson EA, Henderson S, et al. A novel 33 gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias. Br J Haematol 2016;175:318-30.
63. Sun Y, Ruivenkamp CA, Hoff er MJ, et al. Next-generation diagnostics: gene panel, exome, or whole genome? Hum Mutat 2015;36:648-55.
64. Bean LJH, Funke B, Carlson CM, et al. Diagnostic gene sequencing panels: from design to report—a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020;22:453-61.